BMC Cancer (Mar 2022)

Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies

  • Bi-Cheng Wang,
  • Bo-Ya Xiao,
  • Guo-He Lin

DOI
https://doi.org/10.1186/s12885-022-09469-5
Journal volume & issue
Vol. 22, no. 1
pp. 1 – 10

Abstract

Read online

Highlights 1. Nearly 44% of relapsed Ewing sarcoma patients achieved an ORR after IT treatment. 2. Relapsed Ewing sarcoma treated with IT had an over 66% DCR. 3. IT chemotherapy caused low incidences of neutropenia, thrombocytopenia, and diarrhea in treating relapsed Ewing sarcoma.

Keywords